Vildagliptin 50 mg Twice Daily in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin
Primary Purpose
Type 2 Diabetes Mellitus
Status
Completed
Phase
Phase 4
Locations
Egypt
Study Type
Interventional
Intervention
vildagliptin
Sponsored by

About this trial
This is an interventional treatment trial for Type 2 Diabetes Mellitus focused on measuring metformin, vildagliptin, T2DM
Eligibility Criteria
Inclusion Criteria:
- Patients who sign the informed consent
- HbA1c in the range of > 7 to ≤10.5% at Visit 1
- Ability to comply with all study requirements
Exclusion Criteria:
- Pregnant or lactating women
- Serious cardiovascular disorders
- Liver/renal disease or dysfunction
- Anti-diabetic other than metformin, thiazolidine, or α-GI or insulin
- Laboratories values abnormalities as defined by the protocol
Sites / Locations
- Investigative site
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Vildagliptin 50 bid
Arm Description
Outcomes
Primary Outcome Measures
Evaluate the safety and tolerability of vildagliptin 50 mg bid
Efficacy of vildagliptin based on the reduction in mean HbA1c and mean fasting plasma glucose with vildagliptin treatment at 12 weeks. Safety is measured by monitoring lipids profile, liver and kidney function to assess vildagliptin safety.
Secondary Outcome Measures
Full Information
NCT ID
NCT01426802
First Posted
July 1, 2011
Last Updated
February 23, 2017
Sponsor
Novartis Pharmaceuticals
1. Study Identification
Unique Protocol Identification Number
NCT01426802
Brief Title
Vildagliptin 50 mg Twice Daily in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin
Official Title
A 12 Week Multi Center, Open Label, Single Arm Study to Assess the Safety and Efficacy of Vildagliptin 50 mg Twice Daily in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin
Study Type
Interventional
2. Study Status
Record Verification Date
February 2017
Overall Recruitment Status
Completed
Study Start Date
October 2010 (undefined)
Primary Completion Date
April 2011 (Actual)
Study Completion Date
April 2011 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Novartis Pharmaceuticals
4. Oversight
5. Study Description
Brief Summary
The study is designed to demonstrate the short term efficacy and safety of vildagliptin 50 mg bid in patients with Type 2 Diabetes Mellitus inadequately controlled with Metformin.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes Mellitus
Keywords
metformin, vildagliptin, T2DM
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
150 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Vildagliptin 50 bid
Arm Type
Experimental
Intervention Type
Drug
Intervention Name(s)
vildagliptin
Intervention Description
Drug 50mg vildagliptin bid
Primary Outcome Measure Information:
Title
Evaluate the safety and tolerability of vildagliptin 50 mg bid
Description
Efficacy of vildagliptin based on the reduction in mean HbA1c and mean fasting plasma glucose with vildagliptin treatment at 12 weeks. Safety is measured by monitoring lipids profile, liver and kidney function to assess vildagliptin safety.
Time Frame
12 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patients who sign the informed consent
HbA1c in the range of > 7 to ≤10.5% at Visit 1
Ability to comply with all study requirements
Exclusion Criteria:
Pregnant or lactating women
Serious cardiovascular disorders
Liver/renal disease or dysfunction
Anti-diabetic other than metformin, thiazolidine, or α-GI or insulin
Laboratories values abnormalities as defined by the protocol
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Novartis Pharmaceuticals
Organizational Affiliation
Novartis Pharmaceuticals
Official's Role
Study Director
Facility Information:
Facility Name
Investigative site
City
Cairo
Country
Egypt
12. IPD Sharing Statement
Learn more about this trial
Vildagliptin 50 mg Twice Daily in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin
We'll reach out to this number within 24 hrs